Page last updated: 2024-09-05

enzastaurin and Sensitivity and Specificity

enzastaurin has been researched along with Sensitivity and Specificity in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hayes, DN; Shores, CG; Yin, X	1
Basche, M; Britten, CD; Carducci, M; Cook, CA; Eckhardt, SG; Green, LJ; Herbst, RS; Jaken, S; Marder, P; Musib, LC; Ray, C; Thornton, D	1

Other Studies

2 other study(ies) available for enzastaurin and Sensitivity and Specificity

Article	Year
Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma. Head & neck, 2011, Volume: 33, Issue:8 Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Disease Models, Animal; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase C beta; Radiation-Sensitizing Agents; Random Allocation; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays	2011
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Enzyme Activators; Enzyme Inhibitors; Flow Cytometry; Fluorouracil; Follow-Up Studies; Humans; Indoles; Leukocytes, Mononuclear; Monocytes; Neoplasms; Protein Kinase C; Protein Kinase C beta; Reproducibility of Results; Sensitivity and Specificity; Signal Transduction; Structure-Activity Relationship; Treatment Outcome	2006

Article

Year

Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma.

Head & neck, 2011, Volume: 33, Issue:8

Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Disease Models, Animal; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase C beta; Radiation-Sensitizing Agents; Random Allocation; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays

2011

Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1

Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Enzyme Activators; Enzyme Inhibitors; Flow Cytometry; Fluorouracil; Follow-Up Studies; Humans; Indoles; Leukocytes, Mononuclear; Monocytes; Neoplasms; Protein Kinase C; Protein Kinase C beta; Reproducibility of Results; Sensitivity and Specificity; Signal Transduction; Structure-Activity Relationship; Treatment Outcome

2006